Literature DB >> 266179

Relative conformational rigidity in oxytocin and (1-penicillamine)-oxytocin: a proposal for the relationship of conformational flexibility to peptide hormone agonism and antagonism.

J P Meraldi, V J Hruby, A I Brewster.   

Abstract

A comparative study of the proton and carbon-13 nuclear magnetic resonance spectral parameters of the peptide hormone oxytocin and of its competitive inhibitor [1-L-penicillamine]oxytocin has been made, and the results analyzed in terms of comparative conformational and dynamic properties. The results indicate that oxytocin has a flexible conformation, while [1-L-penicillamine]oxytocin has a more restricted conformation. The results provide a framework for understanding the mechanism of peptide hormone agonism and antagonism for these compounds, and an approach for understanding some features of the interaction of the hormone and related compounds with their receptor.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 266179      PMCID: PMC430763          DOI: 10.1073/pnas.74.4.1373

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Synthesis of specifically deuterated S-benzylcysteines and of oxytocin and related diastereomers deuterated in the half-cystine positions.

Authors:  D A Upson; V J Hruby
Journal:  J Org Chem       Date:  1976-04-16       Impact factor: 4.354

2.  Letter: Studies on the molecular association of oxytocin and related compounds in dimethyl sulfoxide.

Authors:  J P Meraldi; V J Hruby
Journal:  J Am Chem Soc       Date:  1976-09-29       Impact factor: 15.419

3.  300-MHz nuclear magnetic resonance study of oxytocin aqueous solution: conformational implications.

Authors:  A I Brewster; V J Hruby
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

4.  Conformational energy studies of oxytocin and its cyclic moiety.

Authors:  D Kotelchuck; H A Scheraga; R Walter
Journal:  Proc Natl Acad Sci U S A       Date:  1972-12       Impact factor: 11.205

5.  Model-building of neurohypophyseal hormones.

Authors:  B Honig; E A Kabat; L Katz; C Levinthal; T T Wu
Journal:  J Mol Biol       Date:  1973-10-25       Impact factor: 5.469

6.  Proposed conformations of oxytocin and selected analogs in dimethyl sulfoxide as deduced from proton magnetic resonance studies.

Authors:  A I Brewster; V J Hruby; J A Glasel; A E Tonelli
Journal:  Biochemistry       Date:  1973-12-18       Impact factor: 3.162

7.  Deuteron magnetic resonance studies on the microdynamical behavior of partially deuterated oxytocin with neurophysin.

Authors:  J A Glasel; V J Hruby; J F McKelvy; A F Spatola
Journal:  J Mol Biol       Date:  1973-09-25       Impact factor: 5.469

8.  The conformational characteristics in solution of the cyclic hexapeptide Gly-Gly-D-Ala-D-Ala-Gly-Gly.

Authors:  A E Tonelli; A I Brewster
Journal:  J Am Chem Soc       Date:  1972-04-19       Impact factor: 15.419

9.  Conformational studies of oxytocin and lysine vasopressin in aqueous solution using high resolution NMR spectroscopy.

Authors:  J Feeney; G C Roberts; J H Rockey; A S Burgen
Journal:  Nat New Biol       Date:  1971-07-28

10.  Conformational studies of oxytocin, lysine vasopressin, arginine vasopressin, and arginine vasotocin by carbon-13 nuclear magnetic resonance spectroscopy.

Authors:  R Walter; K U Prasad; R Deslauriers; I C Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1973-07       Impact factor: 11.205

View more
  11 in total

Review 1.  Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations.

Authors:  V J Hruby; F al-Obeidi; W Kazmierski
Journal:  Biochem J       Date:  1990-06-01       Impact factor: 3.857

Review 2.  Trends in peptide drug discovery.

Authors:  Markus Muttenthaler; Glenn F King; David J Adams; Paul F Alewood
Journal:  Nat Rev Drug Discov       Date:  2021-02-03       Impact factor: 84.694

Review 3.  Ligand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptors.

Authors:  Christian W Gruber; Markus Muttenthaler; Michael Freissmuth
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

4.  Quality Control of Therapeutic Peptides by 1H NMR HiFSA Sequencing.

Authors:  Mary P Choules; Jonathan Bisson; Wei Gao; David C Lankin; James B McAlpine; Matthias Niemitz; Birgit U Jaki; Scott G Franzblau; Guido F Pauli
Journal:  J Org Chem       Date:  2019-02-22       Impact factor: 4.354

Review 5.  Organic chemistry and biology: chemical biology through the eyes of collaboration.

Authors:  Victor J Hruby
Journal:  J Org Chem       Date:  2009-12-18       Impact factor: 4.354

6.  Effects of conformational constraint in 2- and 8-cycloleucine analogues of oxytocin and [1-penicillamine] oxytocin examined by circular dichroism and bioassay.

Authors:  I Fric; J Hlavacek; T W Rockway; W Y Chan; V J Hruby
Journal:  J Protein Chem       Date:  1990-02

Review 7.  Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs.

Authors:  V J Hruby
Journal:  Mol Cell Biochem       Date:  1982-04-16       Impact factor: 3.396

8.  [half-Cys4,half-Cys10]-alpha-Melanocyte-stimulating hormone: a cyclic alpha-melanotropin exhibiting superagonist biological activity.

Authors:  T K Sawyer; V J Hruby; P S Darman; M E Hadley
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

9.  Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors.

Authors:  H I Mosberg; R Hurst; V J Hruby; K Gee; H I Yamamura; J J Galligan; T F Burks
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

10.  Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism.

Authors:  Joanna Gajewiak; Sean B Christensen; Cheryl Dowell; Fuaad Hararah; Fernando Fisher; Peter N Huynh; Baldomero M Olivera; J Michael McIntosh
Journal:  J Med Chem       Date:  2021-06-18       Impact factor: 8.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.